Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF17, J6M0(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9540MR)

This product GTTS-WQ9540MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF17 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001192.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 608
UniProt ID Q02223
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF17, J6M0(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9540MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5269MR IVTScrip™ mRNA-Anti-IL4-α, CD124(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CD124
GTTS-WQ12311MR IVTScrip™ mRNA-Anti-CSF2, MT203(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MT203
GTTS-WQ6410MR IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CT-011
GTTS-WQ4410MR IVTScrip™ mRNA-Anti-TNFRSF9, BMS-663513(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-663513
GTTS-WQ8074MR IVTScrip™ mRNA-Anti-CD33, h2H12ec(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA h2H12ec
GTTS-WQ15998MR IVTScrip™ mRNA-Anti-ERBB2, ZW-25(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ZW-25
GTTS-WQ8981MR IVTScrip™ mRNA-Anti-IL22, ILV-094(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ILV-094
GTTS-WQ14466MR IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA RO-7105705
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW